Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced voting results from its annual and special meeting of shareholders held Sept. 22, 2026, with 46,452,598 common shares represented, or 63.58% of outstanding shares as of the record date. According to the company, shareholders appointed Zeifmans LLP as auditor, approved setting the board at eight directors and elected Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So as directors. Shareholders also approved changing the company’s legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1.
The legal name change follows adoption of the Helus Pharma business name on Jan. 5 and reflects the company’s anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. This shift is significant because it signals that Helus Pharma is moving closer to bringing its therapies to market, potentially accelerating revenue generation and altering its risk profile for investors. The company’s proprietary novel serotonergic agonists (NSAs) are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity, addressing the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom and Ireland.
For Company updates and to learn more about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company’s newsroom at https://nnw.fm/HELP.
The announcement was disseminated through NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The full press release can be viewed at https://nnw.fm/H4DVg, and the company’s newsroom is available at Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP). Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
